Arakyta

Arakyta is a New Haven-based biotechnology company dedicated to the discovery and development of novel therapeutics targeting the complement system. The company was co-founded by Dr. Leonard Bell, the founder and former CEO of Alexion Pharmaceuticals, bringing unparalleled expertise in the field of complement-mediated rare diseases. Arakyta's mission is to develop next-generation inhibitors that offer improved efficacy, safety, and patient convenience compared to existing standards of care. While currently operating in a relatively stealthy capacity, the company is advancing a pipeline of candidates designed to address high-value indications in immunology, hematology, and nephrology. Arakyta leverages its founders' deep historical success in the orphan drug space to identify and validate new therapeutic opportunities within the complement cascade.